vs
Legacy Education Inc.（LGCY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Legacy Education Inc.的1.6倍（$30.3M vs $19.2M），Legacy Education Inc.净利率更高（10.6% vs -221.3%，领先232.0%），REGENXBIO Inc.同比增速更快（43.0% vs 40.7%），Legacy Education Inc.自由现金流更多（$512.7K vs $-52.8M）
Legacy Education Inc.是一家专业教育培训服务商，主打财商素养、房地产投资、创业、个人财富管理相关课程，主要服务北美、欧洲及部分亚太地区的个人学习者，提供线下研讨会和线上数字化课程，帮助用户掌握实用的金融与商业技能。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LGCY vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$19.2M
营收增速更快
RGNX
高出2.3%
40.7%
净利率更高
LGCY
高出232.0%
-221.3%
自由现金流更多
LGCY
多$53.3M
$-52.8M
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.2M | $30.3M |
| 净利润 | $2.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 13.3% | -190.0% |
| 净利率 | 10.6% | -221.3% |
| 营收同比 | 40.7% | 43.0% |
| 净利润同比 | 46.0% | -31.2% |
| 每股收益（稀释后） | $0.15 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGCYRGNX
| Q4 25 | $19.2M | $30.3M | ||
| Q3 25 | $19.4M | $29.7M | ||
| Q2 25 | $18.0M | $21.4M | ||
| Q1 25 | $18.6M | $89.0M | ||
| Q4 24 | $13.6M | $21.2M | ||
| Q3 24 | $14.0M | $24.2M | ||
| Q2 24 | — | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润LGCYRGNX
| Q4 25 | $2.0M | $-67.1M | ||
| Q3 25 | $2.2M | $-61.9M | ||
| Q2 25 | $1.2M | $-70.9M | ||
| Q1 25 | $2.8M | $6.1M | ||
| Q4 24 | $1.4M | $-51.2M | ||
| Q3 24 | $2.1M | $-59.6M | ||
| Q2 24 | — | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率LGCYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率LGCYRGNX
| Q4 25 | 13.3% | -190.0% | ||
| Q3 25 | 13.9% | -176.3% | ||
| Q2 25 | 11.1% | -296.3% | ||
| Q1 25 | 19.7% | 13.6% | ||
| Q4 24 | 12.2% | -242.1% | ||
| Q3 24 | 19.1% | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率LGCYRGNX
| Q4 25 | 10.6% | -221.3% | ||
| Q3 25 | 11.3% | -208.3% | ||
| Q2 25 | 6.8% | -331.8% | ||
| Q1 25 | 15.2% | 6.8% | ||
| Q4 24 | 10.3% | -241.3% | ||
| Q3 24 | 14.9% | -246.3% | ||
| Q2 24 | — | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）LGCYRGNX
| Q4 25 | $0.15 | $-1.30 | ||
| Q3 25 | $0.16 | $-1.20 | ||
| Q2 25 | $0.07 | $-1.38 | ||
| Q1 25 | $0.21 | $0.12 | ||
| Q4 24 | $0.10 | $-0.99 | ||
| Q3 24 | $0.21 | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.1M | $230.1M |
| 总债务越低越好 | $660.3K | — |
| 股东权益账面价值 | $46.1M | $102.7M |
| 总资产 | $73.1M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资LGCYRGNX
| Q4 25 | $21.1M | $230.1M | ||
| Q3 25 | $20.6M | $274.2M | ||
| Q2 25 | $20.3M | $323.3M | ||
| Q1 25 | $17.3M | $267.9M | ||
| Q4 24 | $16.9M | $234.7M | ||
| Q3 24 | $21.5M | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务LGCYRGNX
| Q4 25 | $660.3K | — | ||
| Q3 25 | $776.9K | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $1.0M | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $758.2K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LGCYRGNX
| Q4 25 | $46.1M | $102.7M | ||
| Q3 25 | $43.7M | $161.5M | ||
| Q2 25 | $41.0M | $213.7M | ||
| Q1 25 | $39.3M | $274.2M | ||
| Q4 24 | $36.4M | $259.7M | ||
| Q3 24 | $32.6M | $301.4M | ||
| Q2 24 | — | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产LGCYRGNX
| Q4 25 | $73.1M | $453.0M | ||
| Q3 25 | $72.1M | $525.2M | ||
| Q2 25 | $69.2M | $581.0M | ||
| Q1 25 | $67.1M | $490.9M | ||
| Q4 24 | $62.1M | $466.0M | ||
| Q3 24 | $50.6M | $519.1M | ||
| Q2 24 | — | $569.4M | ||
| Q1 24 | — | $629.2M |
负债/权益比LGCYRGNX
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 0.03× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $512.7K | $-52.8M |
| 自由现金流率自由现金流/营收 | 2.7% | -174.0% |
| 资本支出强度资本支出/营收 | 2.8% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.52× | — |
| 过去12个月自由现金流最近4个季度 | $4.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LGCYRGNX
| Q4 25 | $1.1M | $-52.3M | ||
| Q3 25 | $1.1M | $-56.0M | ||
| Q2 25 | $3.0M | $-49.3M | ||
| Q1 25 | $918.7K | $33.6M | ||
| Q4 24 | $659.0K | $-31.6M | ||
| Q3 24 | $3.2M | $-40.5M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流LGCYRGNX
| Q4 25 | $512.7K | $-52.8M | ||
| Q3 25 | $809.7K | $-56.5M | ||
| Q2 25 | $2.9M | $-49.7M | ||
| Q1 25 | $596.6K | $32.6M | ||
| Q4 24 | $466.8K | $-32.7M | ||
| Q3 24 | $2.9M | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率LGCYRGNX
| Q4 25 | 2.7% | -174.0% | ||
| Q3 25 | 4.2% | -189.9% | ||
| Q2 25 | 16.2% | -232.8% | ||
| Q1 25 | 3.2% | 36.6% | ||
| Q4 24 | 3.4% | -154.2% | ||
| Q3 24 | 21.1% | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度LGCYRGNX
| Q4 25 | 2.8% | 1.7% | ||
| Q3 25 | 1.3% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 1.7% | 1.2% | ||
| Q4 24 | 1.4% | 5.1% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率LGCYRGNX
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 2.45× | — | ||
| Q1 25 | 0.33× | 5.53× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGCY
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
